Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial

by Vandana Singh, Benzinga Editor

September 13, 2022 11:58 AM | 1 min read | Make a Comment

Vaxxinity Inc VAXX announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine targeting calcitonin gene-related peptide (CGRP), for the preventive treatment of migraine.
The Phase 1 randomized, placebo-controlled, double-blind, multidose trial will enroll approximately 40 healthy volunteers in Belgium.
The trial's objectives are to evaluate safety, tolerability, and immunogenicity. Serum anti-CGRP antibody titers will measure immunogenicity. Pharmacodynamics of the immune response will be measured by the inhibition of the capsaicin-induced increase in dermal blood flow, an established model of target engagement in migraine.
Price Action: VAXX shares are trading 2.09% higher at $2.20 on the last check Tuesday.

Posted In: Biotech News Penny Stocks Health Care General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.